Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Sara Lonardi

Sara Lonardi

Veneto Institute of Oncology - IRCCS

CheckMate 8HW: nivolumab & ipilimumab in MSI-H/dMMR metastatic CRC

CheckMate 8HW: nivolumab & ipilimumab in MSI-H/dMMR metastatic CRC

Sara Lonardi • 22 Oct 2025

Safety concerns of using HER2-targeting therapies in gastrointestinal cancers

Safety concerns of using HER2-targeting therapies in gastrointestinal cancers

Sara Lonardi • 10 Jul 2024

Biomarker-driven treatment strategies for HER2+ G/GEJ junction cancer

Biomarker-driven treatment strategies for HER2+ G/GEJ junction cancer

Sara Lonardi • 10 Jul 2024

Advancements in immunotherapy for metastatic colorectal cancer

Advancements in immunotherapy for metastatic colorectal cancer

Sara Lonardi • 10 Jul 2024

Elucidating the optimal second-line therapy in metastatic pancreatic cancer

Elucidating the optimal second-line therapy in metastatic pancreatic cancer

Sara Lonardi • 1 Jul 2024

HRQoL findings from CheckMate 8HW: nivolumab and ipilimumab in MSI-H/dMMR mCRC

HRQoL findings from CheckMate 8HW: nivolumab and ipilimumab in MSI-H/dMMR mCRC

Sara Lonardi • 1 Jul 2024